Document is current
Any future updates will be listed below
-
Authors
Lui, Matthew
Kim, Noah
Zaghlol, Raja
Joolharzadeh, Pouya
Deych, Elena
Robinson, Clifford
Badiyan, Shahed
Woodard, Pamela K.
Mitchell, Joshua D.
-
Funding
Funding for this research was provided by:
National Center for Advancing Translational Sciences of the National Institutes of Health (UL1TR002345)
- License Information
-
More Information
Article History
Received: 13 August 2024
Accepted: 30 October 2024
First Online: 12 November 2024
Declarations
:
: CR: Stock in EmpNia, Radialogica, and Quantaras. Leadership roles in EmpNia and Radialogica. Modest consulting from AstraZeneca, EMD Serono, Quantaras and Varian Medical Systems, unrelated to the manuscript. Research support from Varian Medical Systems and Merck, unrelated to the manuscript. JM: Modest consulting from Alnylam, Altathera, BridgeBio, Pfizer, and Race Oncology, unrelated to the manuscript. Research support from Abbott Laboratories and Myocardial Solutions, unrelated to the manuscript. SB: Speaker’s honoraria from Reflexion, unrelated to the manuscript. Research funding from Astra Zeneca, unrelated to the manuscript. Modest consulting from Merck, unrelated to the manuscript. The remaining authors have nothing to disclose.
